A study to investigate the preventive effect of AG-1749 against the onset of gastric and duodenal ulcers that can be seen during long-term treatment with low dose aspirin.

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220484

Enrollment

812

Registered

2007-12-13

Start date

2007-12-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients that require long-term low-dose aspirin treatment to manage thrombosis, thrombus formation etc., after angina, myocardial infarction, ischemic cerebrovascular disorder, coronary artery bypass surgery or percutaneous transluminal coronary angioplasty.

Interventions

investigational material(s) Generic name etc : AG-1749 (Lansoprazole) INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investiga

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The patient was on low-dose aspirin treatment on the day when consent was obtained, and requires the long-term continuous treatment even after treatment with the investigational drug is started. 2) The patient was confirmed to have a history of gastric ulcer or duodenal ulcer (combined gastric and duodenal ulcer is also possible).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Frequency of gastric or duodenal ulcer	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026